Cerebrolysin

What it is

Cerebrolysin is a proprietary injectable preparation derived from porcine brain hydrolysate. Unlike single-sequence peptides such as semaglutide, SS-31, or ARA-290, Cerebrolysin is a complex mixture of low-molecular-weight peptides and free amino acids^{[4 –5 ]}. It has been marketed and used by prescription in some jurisdictions outside the United States, particularly in neurologic contexts such as stroke, dementia, cognitive impairment, and traumatic brain injury^{[1 ,4 –7 ]}.

The proposed mechanism is neurotrophic and neuroprotective rather than a single receptor-ligand mechanism. Reviews describe pharmacodynamic properties intended to resemble endogenous neurotrophic factors, with research interest in neuronal survival, plasticity, and recovery after neurologic injury^{[4 –7 ]}. Because the product is a mixture, mechanism claims are less straightforward than for a single active ingredient with a defined receptor target, binding affinity, and dose-response relationship.

Cerebrolysin is often discussed in nootropic and recovery communities as a “brain repair” peptide. That framing is broader than the evidence supports and can obscure major jurisdictional differences. The manufacturer’s website includes a notice to US visitors stating that Cerebrolysin is not registered with FDA and is not approved for sale or distribution in the United States^{[1 ]}. Non-US marketing and prescribing information do not create US approval.

The manufacturer states that Cerebrolysin is a prescription medication for use under the supervision of an authorized healthcare professional^{[1 ]}. In the Austrian prescribing-information summary on the manufacturer’s site, Cerebrolysin is listed as a solution for injection, and the page states that it is available only on prescription and in pharmacies^{[1 ]}. This page describes regulatory status and published research only and does not provide dosing, importing, or administration guidance.

Cerebrolysin is best understood as an adjacent peptide-based biologic preparation rather than a simple synthetic peptide. That distinction matters for manufacturing, batch consistency, analytical characterization, immunogenicity, animal-derived product controls, and CMS taxonomy. It should not be grouped uncritically with single-molecule research peptides.

Regulatory status

Cerebrolysin is not FDA-approved for any indication in the United States. The manufacturer’s US visitor notice states that Cerebrolysin is not registered with FDA and is not approved for sale or distribution in the United States^{[1 ]}.

US import and approval

FDA’s general import framework requires imported human drugs to meet FDA requirements for approval, labeling, registration/listing, and manufacturing quality. FDA has repeatedly explained that unapproved new drugs generally cannot be legally marketed or imported for US use without an applicable FDA authorization pathway^{[2 –3 ]}. Cerebrolysin should therefore not be presented as a routine US prescription option.

Compounding pathway

Cerebrolysin is not a typical pharmacy-compounding peptide. It is a proprietary animal-derived mixture rather than a single bulk drug substance. It was not identified on the FDA 503A category list or as a 503B bulk-substance pathway in the FDA materials reviewed for this draft^{[2 –3 ]}. A US clinician generally cannot prescribe an unapproved foreign drug as if it were an FDA-approved product; lawful clinical use would require an appropriate investigational or other FDA-authorized pathway.

Non-US prescription context

The manufacturer describes the Austrian product as prescription-only and lists therapeutic indications in the Austrian Summary of Product Characteristics context, including cerebrovascular disorders, Alzheimer-type senile dementia, vascular dementia, stroke, and craniocerebral trauma^{[1 ]}. Those non-US indications are important context for international readers but should not be converted into US approval language.

Cerebrolysin was not identified in the federal controlled-substance schedules in 21 CFR Part 1308 as reviewed on May 7, 2026^{[8 ]}. Controlled-substance status is separate from FDA approval, import legality, prescription status, and product authenticity. Date of last regulatory verification: May 7, 2026.

Research summary

Acute ischemic stroke — Cochrane 2023

Acute ischemic stroke has the largest systematic-review literature. The 2023 Cochrane review describes Cerebrolysin as a mixture of low-molecular-weight peptides and amino acids derived from porcine brain and notes its use in Russia, Eastern Europe, China, and other Asian and post-Soviet countries^{[5 ]}. The review concluded that adding Cerebrolysin or a Cerebrolysin-like agent to standard therapy probably does not reduce the risk of death and may increase serious non-fatal adverse events^{[5 ]}. This is substantially more cautious than many promotional summaries.

Post-stroke rehabilitation — Mitrovic 2023

Post-stroke rehabilitation studies have reported more positive findings in selected populations. Mitrovic and colleagues conducted a randomized, double-blind, placebo-controlled study of 60 patients in early severe subacute stroke rehabilitation, comparing Cerebrolysin plus rehabilitation with placebo plus rehabilitation^{[7 ]}. The study reported improved upper-limb motor recovery with the combined approach^{[7 ]}. This is clinically relevant but small and should be weighed against broader systematic-review conclusions.

Vascular dementia — Cochrane 2019

Vascular dementia has also been reviewed by Cochrane. The 2019 update evaluated randomized controlled trials and found evidence limitations, including heterogeneity and uncertainty for important outcomes^{[6 ]}. The review described Cerebrolysin as a porcine brain-derived preparation said to have neurotrophic and neuroprotective activity, but did not establish it as a definitive treatment for vascular dementia^{[6 ]}.

Alzheimer and mixed dementia — Plosker 2009

Alzheimer disease and mixed dementia evidence includes older randomized trials summarized in a 2009 review by Plosker and Gauthier^{[4 ]}. That review described Cerebrolysin as a parenterally administered porcine brain-derived peptide preparation and reported benefits on some global and cognitive measures in dementia trials^{[4 ]}. However, the review predates many current dementia-trial standards, current disease-modifying antibody debates, and modern US regulatory expectations. It should not be treated as equivalent to FDA approval.

Calibration

Trial interpretation is complicated by the product category. Cerebrolysin is a complex animal-derived mixture rather than a single chemically defined active pharmaceutical ingredient^{[4 –5 ]}. For single-molecule drugs, reviewers can often connect a dose, receptor target, exposure, and outcome with more precision. For Cerebrolysin, clinical findings depend on product manufacturing consistency, peptide and amino-acid composition, background standard of care, rehabilitation intensity, timing after injury, and regional trial practice.

Outcome selection also matters. Stroke, dementia, TBI, and rehabilitation studies may use mortality, serious adverse events, neurologic impairment scales, activities-of-daily-living measures, caregiver-rated global outcomes, cognitive tests, or motor-recovery endpoints^{[4 –7 ]}. A positive signal on one scale does not necessarily imply disease modification, functional independence, survival benefit, or durable cognitive improvement. The Cochrane stroke review’s adverse-event conclusion should therefore remain visible even when discussing smaller positive rehabilitation trials^{[5 ,7 ]}.

Product authenticity

Product authenticity has also been studied. Gevaert and colleagues analyzed internet-obtained Cerebrolysin using peptide-profiling methods and found that analytical techniques could profile products obtained outside conventional supply channels^{[9 ]}. This kind of work is relevant because US users may encounter Cerebrolysin through importers or online sellers rather than regulated domestic pharmacy channels.

For a US reference site, the regulatory and evidence summaries should be kept separate. Cerebrolysin’s non-US prescription history and substantial trial literature make it more evidence-rich than many online “research peptides”^{[1 ,4 –7 ]}. At the same time, FDA has not reviewed it as an approved US drug, and Cochrane reviews remain cautious for major neurologic indications^{[5 –6 ]}. A balanced page should therefore avoid both extremes: it should not present Cerebrolysin as a standard US neurologic therapy, and it should not imply that the product has no clinical literature.

Overall, Cerebrolysin has a larger clinical literature than most grey-market peptides, but it remains non-FDA-approved in the United States. The evidence should be presented as mixed by indication. Systematic reviews should carry more weight than single positive trials, and non-US prescribing context should be separated from US regulatory status.

Public discourse

Cochrane Stroke review authors gave a cautious assessment of mortality and serious adverse events in acute ischemic stroke trials^{[5 ]}.

EVER Neuro Pharma, the manufacturer, explicitly states the US regulatory limitation in its US-visitor notice^{[1 ]}.

Greg L. Plosker and Serge Gauthier, dementia review authors, summarized dementia-trial evidence and described Cerebrolysin’s product category^{[4 ]}.

Cochrane Dementia review authors evaluated randomized vascular dementia studies and emphasized evidence limitations^{[6 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Cerebrolysin has no FDA-approved US prescribing information. There is no FDA-reviewed US label establishing approved indications, contraindications, adverse reactions, drug interactions, pregnancy safety, monitoring requirements, or manufacturing controls^{[1 –3 ]}.

Non-US prescribing information

The manufacturer summary based on Austrian prescribing information lists contraindications including hypersensitivity to a component, epilepsy, and severe renal impairment^{[1 ]}. These are non-US prescribing-information details and should be verified against local product information if discussing non-US use^{[1 ]}.

Tolerability in published trials

The 2009 dementia review described Cerebrolysin as generally well tolerated in trials, with dizziness or vertigo among the most frequently reported adverse events^{[4 ]}. The 2023 Cochrane acute ischemic stroke review was more cautious and concluded that Cerebrolysin probably increases serious non-fatal adverse events^{[5 ]}.

Animal-derived mixture concerns

Animal-derived complex mixtures raise quality and identity questions distinct from single synthetic peptides. Product source, manufacturing controls, batch consistency, viral or prion risk controls, storage, authenticity, and peptide profile are all relevant. These issues are especially important for online or imported products.

Long-term safety

The absence of US labeling also means there is no FDA-vetted framework for renal impairment, seizure history, concomitant anticoagulation or antiplatelet therapy after stroke, pregnancy, lactation, pediatric use, geriatric frailty, or use alongside rehabilitation programs. Those topics should be handled by clinicians familiar with the jurisdiction and product label, not by consumer dosing protocols.

Long-term safety data in US clinical practice are absent because Cerebrolysin is not FDA-approved or marketed in the United States^{[1 –3 ]}. Self-importation or purchase from online pharmacies introduces legal and medical risks related to authenticity, cold-chain handling, labeling, and adverse-event accountability.

Available through

This peptide preparation is not currently available through FDA-compliant channels in the United States. ProPeptideGuide does not link to or endorse grey-market vendors.

No provider-platform listings should be added unless legal review identifies a compliant FDA-authorized investigational or access pathway. ProPeptideGuide does not link to or endorse imported Cerebrolysin sellers, online pharmacies, research-chemical vendors, or clinics advertising noncompliant US access.